Investing in therapeutic development in established fields with well-understood mechanisms can offer lower risk and moderate patient benefits. mTOR inhibition, a prime example, shows potential for modest gains in longevity. While safer investments may yield incremental progress, the longevity industry is still relatively conservative in exploring mTOR inhibitors compared to riskier reprogramming approaches.
Hevolution, a Saudi Arabian fund, is considering a $1 billion investment in longevity-enhancing therapies. Despite previous focus on academic research funding, the fund is now venturing into funding companies like Aeovian Pharmaceuticals, emphasizing a conservative and safe investment strategy.
Hevolution Foundation’s $20 million investment in Aeovian Pharmaceuticals to advance selective mTORC1 inhibitors highlights their dedication to developing safe and effective aging therapies. This investment, part of a larger Series A financing extension, aims to address various age-related diseases, showcasing a commitment to advancing healthspan through strategic collaborations.
